<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1082">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838301</url>
  </required_header>
  <id_info>
    <org_study_id>Allo-20-001</org_study_id>
    <secondary_id>R01AG063826</secondary_id>
    <nct_id>NCT04838301</nct_id>
  </id_info>
  <brief_title>Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease</brief_title>
  <acronym>REGEN-BRAIN©</acronym>
  <official_title>Safety and Efficacy of Allopregnanolone (Allo) as a Regenerative Therapeutic for Alzheimer's Disease: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ADM Diagnostics, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety&#xD;
      and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a proof-of-concept phase 2 clinical trial to investigate the long-term safety and&#xD;
      efficacy of Allo to function as a regenerative therapeutic to restore structural integrity&#xD;
      and cognitive function of the brain in participants with mild Alzheimer's disease (AD)&#xD;
      dementia. Study participants will be male and female, APOE ε4 positive diagnosed with&#xD;
      probable AD, Mini-Mental State Exam (MMSE) 20 to 26, ages 55 to 80 years old.&#xD;
&#xD;
      After a 2-4-week screening period, participants will be randomized to 4 mg Allo (administered&#xD;
      intravenously over 30 minutes, once per week, in clinic) or matching placebo, 1:1 allocation,&#xD;
      for a period of 12 months. After 12 months, all participants in the placebo group will be&#xD;
      crossed-over to receive Allo for the remainder of the study (6 month open-label phase). Brain&#xD;
      imaging to evaluate the primary endpoint will be conducted at baseline, 6 and 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2023</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are assigned to the active intervention or placebo in parallel for 12 months. After 12 months, all participants in the placebo group will be crossed-over to receive Allo for the remainder of the study (6 month open-label phase).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>After 12 months participants and study personnel will be aware of the open label phase, but initial randomization will remain blind during the entire length of the study (placebo-controlled and open-label periods); that is, all participants and study personnel are blinded to each participant's randomization to initial treatment group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hippocampal volume</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>mm3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cambridge Cognition's Paired Associates Learning Test</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Total errors score (adjusted) - number of errors made by the participant (range: 0 to ~120). Higher scores indicate poor performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cambridge Neuropsychological Test Automated Battery (CANTAB)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Composite score (higher score indicate better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) 11</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Total score (range 0 to 70); higher scores indicate poor performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Cooperative Study (ADCS) Instrumental Activities of Daily (iADL) Living (iADL)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>iADL subscore (range 0-56): Lower score indicates greater severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Frequency of adverse events and serious adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Other regional brain volumes</measure>
    <time_frame>Baseline to 12 and 18 months</time_frame>
    <description>Change in regional brain volumes (mm3)</description>
  </other_outcome>
  <other_outcome>
    <measure>Diffusion tensor imaging (DTI)</measure>
    <time_frame>Baseline to 12 and 18 months</time_frame>
    <description>Change in white matter tract diffusion (scalar values and/or mm2/sec)</description>
  </other_outcome>
  <other_outcome>
    <measure>Resting state functional MRI</measure>
    <time_frame>Baseline to 12 and 18 months</time_frame>
    <description>Change in functional connectivity (z transformed correlations)</description>
  </other_outcome>
  <other_outcome>
    <measure>Arterial spin labeling (ASL)</measure>
    <time_frame>Baseline to 12 and 18 months</time_frame>
    <description>Change in regional cerebral blood flow (mL/100g)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory blood based biomarkers</measure>
    <time_frame>Baseline to 12 and 18 months</time_frame>
    <description>Change from baseline in biomarkers of AD pathology, neurogenesis and inflammation</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Dementia Rating (CDR)</measure>
    <time_frame>Baseline to 12 and 18 months</time_frame>
    <description>Sum of boxes score (CDR-SB): range 0-18</description>
  </other_outcome>
  <other_outcome>
    <measure>Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) 14</measure>
    <time_frame>Baseline to 12 and 18 months</time_frame>
    <description>Total score (range 0-90)</description>
  </other_outcome>
  <other_outcome>
    <measure>Mini Mental State Examination (MMSE)</measure>
    <time_frame>Baseline to 12 and 18 months</time_frame>
    <description>Total score (range 0-30)</description>
  </other_outcome>
  <other_outcome>
    <measure>Neuropsychiatric Inventory-Questionnaire (NPI-Q)</measure>
    <time_frame>Baseline to 12 and 18 months</time_frame>
    <description>Total score (range 0-36). Higher scores indicate greater symptom severity</description>
  </other_outcome>
  <other_outcome>
    <measure>EuroQol 5-Dimension / 5-Level health-related quality of life scale scores (EQ-5D-5L)</measure>
    <time_frame>Baseline to 12 and 18 months</time_frame>
    <description>Reported as frequency, percentage and index value.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life in Alzheimer's Disease scale (QoL-AD)</measure>
    <time_frame>Baseline to 12 and 18 months</time_frame>
    <description>Total score (range 13-52). Higher score indicate better QoL</description>
  </other_outcome>
  <other_outcome>
    <measure>Zarit Burden Interview (ZBI)</measure>
    <time_frame>Baseline to 12 and 18 months</time_frame>
    <description>Total score (range 0-48). Higher scores indicate high burden</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Alzheimer Dementia</condition>
  <condition>Late Onset Alzheimer Disease</condition>
  <condition>Neurodegenerative Diseases</condition>
  <arm_group>
    <arm_group_label>Allo group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allopregnanolone 4mg IV 30-minute infusion once per week for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline) IV 30-minute infusion once per week for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopregnanolone</intervention_name>
    <description>Allopregnanolone 4mg IV via 30-minute infusion, once per week.</description>
    <arm_group_label>Allo group</arm_group_label>
    <other_name>Allo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline solution IV via 30-minute infusion, once per week</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and postmenopausal women&#xD;
&#xD;
          -  Age 55 to 80 years old&#xD;
&#xD;
          -  Meets NIA-AA criteria for probable AD dementia&#xD;
&#xD;
          -  MMSE of 20-26&#xD;
&#xD;
          -  APOE ε4 positive&#xD;
&#xD;
          -  Geriatric Depression Scale short form (GDS-S) score of ≤ 6&#xD;
&#xD;
          -  No medical contraindications to participation&#xD;
&#xD;
          -  Capacity to provide informed consent at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dementia other than probable AD&#xD;
&#xD;
          -  Use of benzodiazepines, anticonvulsants, antipsychotics, or other drugs that might&#xD;
             interact with the GABA-A receptor complex&#xD;
&#xD;
          -  History of stroke with a modified Hachinski Ischemic Scale score &gt;4&#xD;
&#xD;
          -  History of seizure disorder, focal brain lesion, traumatic brain injury&#xD;
&#xD;
          -  History within the last 5 years of a primary or recurrent malignant disease&#xD;
&#xD;
          -  Unstable or clinically significant cardiovascular, kidney or liver disease&#xD;
&#xD;
          -  MRI indicative of any other significant abnormality, including but not limited to one&#xD;
             or more significant ARIA-E or macro-hemorrhage findings, or multiple microhemorrhages&#xD;
             (&gt;8), or Fazekas score of 3; encephalomalacia, aneurysms, vascular malformations,&#xD;
             subdural hematoma, or space occupying lesions&#xD;
&#xD;
          -  Any conditions that would contraindicate MRI studies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Hernandez GD, Solinsky CM, Mack WJ, Kono N, Rodgers KE, Wu CY, Mollo AR, Lopez CM, Pawluczyk S, Bauer G, Matthews D, Shi Y, Law M, Rogawski MA, Schneider LS, Brinton RD. Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical trial. Alzheimers Dement (N Y). 2020 Dec 16;6(1):e12107. doi: 10.1002/trc2.12107. eCollection 2020.</citation>
    <PMID>33344752</PMID>
  </reference>
  <reference>
    <citation>Brinton RD. Neurosteroids as regenerative agents in the brain: therapeutic implications. Nat Rev Endocrinol. 2013 Apr;9(4):241-50. doi: 10.1038/nrendo.2013.31. Epub 2013 Feb 26. Review.</citation>
    <PMID>23438839</PMID>
  </reference>
  <reference>
    <citation>Brinton RD, Wang JM. Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer's disease: allopregnanolone as a proof of concept neurogenic agent. Curr Alzheimer Res. 2006 Jul;3(3):185-90. Review.</citation>
    <PMID>16842093</PMID>
  </reference>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>May 23, 2022</last_update_submitted>
  <last_update_submitted_qc>May 23, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Arizona</investigator_affiliation>
    <investigator_full_name>Roberta Brinton</investigator_full_name>
    <investigator_title>Director, Center for Innovation in Brain Science; Professor, Departments of Pharmacology and Neurology</investigator_title>
  </responsible_party>
  <keyword>Mild Alzheimer Disease</keyword>
  <keyword>Regenerative Therapeutic</keyword>
  <keyword>APOE ε4</keyword>
  <keyword>Neurogenesis</keyword>
  <keyword>Allopregnanolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnanolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

